Vasodilators and beta-blockers increase AMD risk

Article

Vasodilators and oral beta-blockers are associated with an increase in the hazard of incidence of early age-related macular degeneration (AMD) and exudative AMD, respectively, according to research recently published online.

Vasodilators and oral beta-blockers are associated with an increase in the hazard of incidence of early age-related macular degeneration (AMD) and exudative AMD, respectively, according to research published online in Ophthalmology.

Researchers from the Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA, conducted a longitudinal population-based study of people aged 43 to 86 years in Beaver Dam, Wisconsin, from 1988 through 1990. As part of the Beaver Dam Eye Study, examinations were performed every 5 years for 20-years; there were 9,676 person-visits over the course of the study. The researchers determined the status of AMD by grading retinal photographs.

After adjusting for factors such as age and gender, the researchers found that using a vasodilator increased in the hazard of incidence of early AMD by 72%, and using an oral beta blocker the increased hazard of incident exudative AMD by 71%.

“If these findings are replicated, it may have implications for care of older adults because vasodilators and oral beta-blockers are drugs that are used commonly by older persons.” the researchers wrote.

To read an abstract of the study, click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.